Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities
Net loss	$ (4,094,833)	$ (3,703,558)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation	87,937	86,444
Write-off of obsolete inventory	79,011
Unrealized (gain)/loss on marketable securities	(54,508)	43,078
Realized loss on marketable equity securities	106,324
Loss on extinguishment of notes		934,257
Stock-based compensation	256,900	333,978
Change in fair value of convertible notes		195,962
Non-cash lease expense	111,984
Changes in operating assets and liabilities:
Accounts receivable, net	9,500
Other receivables	(25,035)	73,850
Prepaid expenses	14,197	(186,056)
Inventory	(20,708)	(21,144)
Other assets	(68,466)	(36,226)
Accounts payable	(248,928)	9,524
Accrued expenses	184,057	280,014
Net cash used in operating activities	(3,662,568)	(1,989,877)
Cash Flows from Investing Activities
Purchases of lab equipment	(40,020)	(14,470)
Purchases of marketable equity securities		(5,976,442)
Purchases of marketable debt securities	(4,014,153)
Sales of marketable equity securities	5,882,138
Net cash provided by (used in) investing activities	1,827,965	(5,990,912)
Cash Flows from Financing Activities
Proceeds from issuance of units and common stock warrants, gross		13,009,621
Payment for issuance costs of units and common stock warrants		(1,627,175)
Payment of non-convertible promissory notes		(270,000)
Proceeds from issuance of convertible notes		250,000
Proceeds from issuance of common stock to underwriters		801,362
Settlement of convertible notes		(141,891)
Proceeds from loan payable - related party		140,000
Payment of loan payable - related party		(166,000)
Net cash provided by financing activities		11,995,917
Net increase (decrease) in cash and cash equivalents	(1,834,603)	4,015,128
Cash and cash equivalents, beginning of period	4,015,128
Cash and cash equivalents, end of period	2,180,525	4,015,128
Supplemental disclosure of cash flow information and non-cash financing transactions
Right-of-use asset acquired through operating lease	1,257,495
Leasehold improvements financed through tenant improvement allowance	312,758
Conversion of notes at initial public offering into common stock		3,222,306
Conversion of preferred stock par value to common stock and additional paid-in capital		58
Fair value of warrants of common stock issued to underwriters		$ 1,647,076